Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Aura Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

AURA PROVIDES PHASE 3 COMPASS TRIAL COMPLETION GUIDANCE: 2026 ENROLLMENT COMPLETION AND Q4 2027 TOPLINE DATA READOUT FOR THE 15-MONTH PRIMARY ENDPOINT

AURA BIOSCIENCES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

ROAD TOWN, BRITISH VIRGIN ISLANDS, OCT. 02, 2025 (GLOBE NEWSWIRE) -- AURA MINERALS INC.(NASDAQ: AUGO; B3: AURA33) (AURA OU COMPANHIA) ANNOUNCES TO THE HOLDERS OF THE COMPANY'S BRAZILIAN DEPOSITARY RECEIPTS ("BDRS") THE LAUNCH OF THE INCENTIVE PROGRAM FOR THE CONVERSION OF BDRS INTO COMMON SHARES (INCENTIVE PROGRAM), UNDER WHICH HOLDERS MAY REQUEST THE CONVERSION OF THEIR BDRS (AURA33) INTO THE UNDERLYING COMMON SHARES (AUGO) LISTED ON NASDAQ (COMMON SHARES), AT A RATIO OF THREE TO ONE, WITHOUT BEING REQUIRED TO PAY THE APPLICABLE FEES CHARGED BY BANCO BRADESCO. THE INCENTIVE PROGRAM WILL BE AVAILABLE FOR A FIXED PERIOD OF 32 DAYS, FROM OCTOBER 6, 2025, TO NOVEMBER 6, 2025 (SUBSIDY PERIOD).

INCENTIVE PROGRAM FOR THE CONVERSION OF BDRS INTO SHARES

THERE IS NO IMPACT TO THE CAPITAL COSTS OR ECONOMIC RESULTS. THE ONLY CHANGE IS A SLIGHTLY REVISED ALL-IN SUSTAINING COST FOR THE "BASE CASE" FROM $1,152 TO $1,172 PER GOLD OUNCE.

Aura Biosciences, Inc.

AURA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Aura Biosciences, Inc.

AURA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AURA